Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones.
This finding was reported in the article “Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes”, which was published online in August 2018 by the medical journal JAMA Internal Medicine.
Among the results stated by medical researchers involved with a recently concluded retrospective cohort study and reported in this medical journal article:
- [N]ew use of sodium-glucose cotransporter 2 inhibitors was associated with a statistically significant increased risk of amputation compared with use of metformin, sulfonylureas, and thiazolidinediones.
- New use of SGLT-2 inhibitors was statistically significantly associated with amputation compared with sulfonylureas, metformin, or thiazolidinediones (adjusted hazard ratio, 2.12; 95% CI, 1.19-3.77).
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have had lower limb amputations (legs, feet, toes) while using Invokana, Jardiance, Farxiga, or any of these other SGLT-2 inhibitors: Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, and Segluromet.[View article at original source]
Strictly Confidential, No Obligation.